Psoriasis is an immune-mediated, inflammatory condition of the skin affecting nearly 3 % of the world’s population. As a chronic disease psoriasis has a substantial effect on the quality of life of patients. More than 80% of patients have mild to moderate psoriasis, for which topical therapies are first line of treatment. Patients with severe psoriasis are eligible for systemic therapies (orals and biologics).
Aim of MC2-01
A fixed dose combination of calcipotriene and betamethasone dipropionate (“Calcipotriene/BDP”) is the best-in-class topical therapy for mild to moderate psoriasis with clinical trial efficacy data matching biologics after 4 weeks and superior to orals. However, current marketed formulations are greasy liquid oils/ointments that patients do not like to use, resulting in non-compliance and poor real-life efficacy.
Using PAD™ Technology and related know-how we have uniquely developed a stabile cream formulation of Calcipotriene/BDP. Our aim is to develop the MC2-01 Cream into a new drug (NDA/MAA) with a superior real-life efficacy and safety profile. MC2-01 Cream is moisturizing, convenient-to-use and it quickly absorbs into the skin allowing patients to move on in daily routines. A solution intended to significantly improve daily quality of life of patients and provide a cost effective treatment.
Ph III trial in the US is being prepared and will commence in 2017.